AstraZeneca PLC — Regulatory Filings 2016

Apr 28, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of April 2016

Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_______

AstraZeneca First Quarter Results 2016

Tomorrow, Friday, 29 April 2016, AstraZeneca will release first quarter results for 2016 at 07:00 bst .

An analyst presentation of the first quarter results will take place at 12:00 bst and will be accessible by a choice of two routes:

Audio play webcast

The presentation will be available to download on the AstraZeneca Investor Relations website http://www.astrazeneca.com/investors/ before the analyst presentation begins.

Teleconference with Q&A . Dial in numbers:

UK (freephone) 0800 376 7922

International: +44 (0) 2071 928000

Sweden (freephone): 020 792 102

USA (freephone): 866 966 1396

Conference ID: 23032512

Details of the teleconference and webcast replay facilities are available on the Investor Relations section of the AstraZeneca website http://www.astrazeneca.com/investors .

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 28 April 2016
Name: Adrian Kemp
Title: Company Secretary